Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | CTSD | P07339 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26581120 | 0.74 | NUDT1 (0.36) | BACE1 | |
| SCHEMBL26427413 | 0.69 | — | — | |
| SCHEMBL18389453 | 0.68 | TSHR (0.41) | TSHRMAPK1CNR1CNR2 | |
| SCHEMBL28365405 | 0.68 | MAOB (0.55) | TSHRMAPK1 | |
| SCHEMBL19806050 | 0.67 | ESR1 (0.33) | CNR2 | |
| SCHEMBL12116527 | 0.66 | CNR2 (0.50) | TSHRMAPK1CNR1CNR2 | |
| SCHEMBL22761783 | 0.66 | HTR2A (0.39) | TSHRMAPK1 | |
| SCHEMBL19806085 | 0.66 | KIF11 (0.35) | TSHRMAPK1 | |
| SCHEMBL19841848 | 0.66 | NR1H4 (0.38) | MAPK1CNR1CNR2 | |
| SCHEMBL13650520 | 0.65 | MAPK1 (0.52) | TSHRMAPK1CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210371375-A1 | hTERT MODULATORS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210371375-A1 | hTERT MODULATORS AND METHODS OF USE | TERT, TERF2, RB1 | TSHR 264/4885MAPK1 2913/4885CNR1 3167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.